Clinical Trials Logo

Clinical Trial Summary

This study evaluates the safety and efficacy of gatifloxacin 0.3% ophthalmic solution compared with ciprofloxacin 0.3% ophthalmic solution in patients with acute bacterial corneal ulcers


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00651586
Study type Interventional
Source Allergan
Contact
Status Completed
Phase Phase 2
Start date October 2003
Completion date April 2005

See also
  Status Clinical Trial Phase
Completed NCT02497365 - Besifloxacin in Bacterial Keratitis N/A
Terminated NCT02088970 - Safety and Efficacity of Corneal Collagen Crosslinking in Infectious Keratitis (Bacterial and Fungal ): Randomized,Controlled, Prospective Study. (CXL) N/A
Recruiting NCT03918408 - Safety and Effectiveness of the PXL-Platinum 330 System for Corneal Collagen Cross-Linking in Eyes With Corneal Thinning Conditions Phase 1
Recruiting NCT02016989 - Matrix Therapy And Bacterial Keratitis N/A
Completed NCT00386958 - A Clinical Trial of Povidone-Iodine for the Treatment of Bacterial Corneal Ulcers Phase 2
Recruiting NCT04213885 - Safety and Effectiveness of the PXL Platinum 330 System for Corneal Collagen Cross-Linking in Eyes With Corneal Thinning Position Phase 2
Completed NCT01831206 - Collagen Cross-linking in Infectious Keratitis Trial Phase 2
Completed NCT03845374 - Prospective, Randomized Multi-Center Study of Using the Hyper-CLâ„¢ Lens in Subjects Suffering From Bacterial Keratitis N/A
Completed NCT00707005 - Antibiotic Susceptibility of Conjunctival Bacterial Isolates From Refractive Surgery Patients N/A
Completed NCT05655689 - The Antibiogram and Outcomes of Antimicrobial Regimens in Microbial Keratitis: A Prospective Cohort Study
Not yet recruiting NCT06271772 - Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction II Phase 3